Clinical Trials Browser

Locally Recurrent Rectal Cancer × Bevacizumab × Clear all

NCT07183865 2025-09-19

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

Phase 2 Recruiting

Gastrointestinal

Locally Recurrent Rectal Cancer

NCT06928584 2025-04-15

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

Phase 2 Recruiting

Gastrointestinal

Locally Recurrent Rectal Cancer